Berikutnya

Putar otomatis

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

2 Tampilan • 07/14/23
Membagikan
Menanamkan
administrator
administrator
Pelanggan
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

Menampilkan lebih banyak
0 Komentar sort Sortir dengan
Komentar Facebook

Berikutnya

Putar otomatis